Antibodies that bind to il1rap and uses thereof
AssigneeIchnos Sciences SA
InventorsJulie MACOIN, Amelie CROSET, Jeremy LOYAU, Thierry MONNEY, Lamine MBOW, Marie-Agnes DOUCEY, Valentina LABANCA
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies which specifically bind to human IL1RAP and my also bind to cynomolgus monkey and/or mouse IL1RAP. The present invention also relates to the use of such antibodies to diagnose and treat human disease.
Claims14
An anti-IL1RAP antibody comprising a first heavy chain CDR region (CDR-H1), a second heavy chain CDR region (CDR-H2), and a third heavy chain CDR region (CDR-H3) selected from the group;
- (a) CDR-H1 comprises an amino acid sequence GFXXXXXXXX (SEQ ID NO:
- 265), wherein X at position 3 can be anyone of amino acids I, T, P;
- X at position 4 can be anyone of amino acids L, F, Y;
- X at position 5 can be anyone of amino acids A, S, P, E, D;
- X at position 6 can be anyone of amino acids V, G, T, H, Q, E, N, D.X at position 7 can be anyone of amino acids F, A, S, Y;
- X at position 8 can be anyone of amino acids A, G, S, P;
- X at position 9 can be anyone of amino acids L, M, A;
- X at position 10 can be anyone of amino acids G, T, S, N;
- (b) CDR-H2 comprises an amino acid sequence AISYDGEGTL (SEQ ID NO:
- 266);
- (c) CDR-H3 comprises an amino acid sequence ARFXYXXAFDY (SEQ ID NO:
- 267), wherein X at position 4 can be anyone of amino acids R, H;
- X at position 6 can be anyone of amino acids Y, R;
- X at position 7 can be anyone of amino acids T, S;
- or
- (d) CDR-H1 comprises an amino acid sequence GXXXXXXAIX (SEQ ID NO:
- 262), wherein X at position 2 can be anyone of amino acids V, G, S, P, E;
- X at position 3 can be anyone of I, L, A, G, T, S, P, H, K, R;
- X at position 4 can be anyone of L, F, A, S, W, H, N, R;
- X at position 5 can be anyone of G, T, S, Y, P, H, E, N, R. X at position 6 be anyone of amino acids V, A, S, P, Q, N, D;
- X at position 7 be anyone of amino acids Y, H;
- X at position 10 be anyone of amino acids H, Q;
- (e) CDR-H2 comprises an amino acid sequence YIIPXXGXXD (SEQ ID NO:
- 263), wherein X at position 5 can be anyone of amino acids T, S;
- X at position 6 can be anyone of amino acids V, L;
- X at position 8 can be anyone of amino acids G, Q;
- X at position 9 can be anyone of amino acids F, Y;
- (f) CDR-H3 comprises an amino acid sequence ARGQTLYXXGRQFDI (SEQ ID NO:
- 264), X at position 8 can be anyone of amino acids A, E, D. X at position 9 can be anyone of amino acids A, T, S;
- and
- wherein said anti-IL1RAP antibody comprises a light chain variable region comprising SEQ ID NO:
- 268.
An anti-IL1RAP antibody comprising a first heavy chain CDR region (CDR-H1), a second heavy chain CDR region (CDR-H2), and a third heavy chain CDR region (CDR-H3), wherein:
- (a) CDR-H1 comprises the amino acid sequence of SEQ ID NO:
- 128;
- (b) CDR-H2 comprises the amino acid sequence of SEQ ID NO:
- 188;
- and
- (c) CDR-H3 comprises the amino acid sequence of SEQ ID NO:
- 248, and wherein said anti-IL1RAP antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 268.
An anti-IL1RAP antibody, wherein the antibody specifically binds to one or more amino acid residues within domain 2 of IL1RAP.
Dependencies are inferred from the claim text.